Picking up the pace: Atea’s $215M series D to fund COVID-19 trial May 20, 2020 By Lee Landenberger No Comments Atea Pharmaceuticals Inc., of Boston, brought in a $215 million series D financing to support development of its COVID-19 antiviral, which is designed to inhibit the viral RNA polymerase enzyme, a key element in RNA virus replication.Read More